QuidelOrtho Corporation
QuidelOrtho Corporation (QDEL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
qdel · pe ratio · data through Dec 28, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for QuidelOrtho Corporation (QDEL) measures how much investors pay for each dollar of the company's trailing earnings. QDEL's current PE ratio of N/A is calculated by dividing its stock price of $14.46 by its TTM earnings per share of -$17.76.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-28
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 12 fiscal years · Front-end computedMinQ1 · 25%25.0x
MedianQ3 · 75%146.1x
Max
At N/A, QDEL's current P/E is lower than in 0% of its annual fiscal year readings over the past 12 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
QuidelOrtho CorporationYou QDEL | $986M | N/A | — | -$17.76 |
 AtriCure, Inc. ATRC | $1.4B | N/A | — | -$0.24 |
 Azenta, Inc. AZTA | $1.0B | N/A | — | -$1.22 |
 Edgewise Therapeutics, Inc. EWTX | $3.7B | N/A | — | -$1.63 |
 Structure Therapeutics Inc. GPCR | $2.2B | N/A | — | -$2.39 |
 LeMaitre Vascular, Inc. LMAT | $2.2B | 31.80x | +28.6% | $2.55 |
 National HealthCare Corporation NHC | $2.9B | 17.67x | -28.6% | $7.76 |
Industry Average 2 peers with valid PE | — | 24.74x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-28Latest FY2025 | — | $-16.69 | — | |
2024-12-29 FY2024 | — | $-30.54 | — | |
2023-12-31 FY2023 | — | $-0.15 | — | |
2023-01-01 FY2023 | 8.87x | $9.66 | +9.9% | |
2021-12-31 FY2021 | 8.07x | $16.74 | -13.6% | |
2020-12-31 FY2020 | 9.34x | $19.24 | -77.8% | |
2019-12-31 FY2019 | 42.04x | $1.78 | +50.1% | |
2018-12-31 FY2018 | 28.00x | $1.74 | — | |
2017-12-31 FY2017 | — | $-0.24 | — | |
2016-12-31 FY2016 | — | $-0.42 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for QuidelOrtho Corporation (QDEL) measures how much investors pay for each dollar of the company's trailing earnings. QDEL's current PE ratio of N/A is calculated by dividing its stock price of $14.46 by its TTM earnings per share of -$17.76.
Frequently asked questions
QDEL pe ratio · 6 questionsQDEL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $14.46 and TTM EPS of -$17.76. Data sourced from Financial Modeling Prep via QDEL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · QuidelOrtho Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08